.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cantor Fitzgerald
Fish and Richardson
Cipla
Citi
Accenture
Novartis
Merck
Teva
UBS

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,665,062

« Back to Dashboard

Summary for Patent: 4,665,062

Title: Method for combating virus infection
Abstract:A method for the selective treatment of virus infections in animals and man and a method of treating cancer caused by viruses, comprising administering to a host so infected a therapeutically effective amount of phosphonoformic acid or a physiologically acceptable salt thereof.
Inventor(s): Eriksson; Bertil F. H. (Sodertalje, SE), Helgstrand; Ake J. E. (Enhorna, SE), Misiorny; Alfons (Bandhagen, SE), Stening; Goran B. (Sodertalje, SE), Stridh; Stig A. (Sodertalje, SE)
Assignee: Astra Lakemedel Aktiebolag (Sodertalje, SE)
Application Number:06/404,295
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,665,062

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden7607496Jul 1, 1976

International Patent Family for Patent: 4,665,062

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
AustriaA465477► Subscribe
Austria369014► Subscribe
Australia510809► Subscribe
Australia2650577► Subscribe
Belgium856355► Subscribe
Bulgaria60834► Subscribe
Canada1077848► Subscribe
Switzerland641471► Subscribe
Germany2728685► Subscribe
Denmark288877► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Federal Trade Commission
McKinsey
Novartis
Argus Health
McKesson
Covington
Cantor Fitzgerald
Cipla
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot